Modality
mRNA
MOA
GLP-1ag
Target
EZH2
Pathway
Tau
Migraine
Development Pipeline
Preclinical
~Oct 2009
→ ~Jan 2011
Phase 1
~Apr 2011
→ ~Jul 2012
Phase 2
~Oct 2012
→ ~Jan 2014
Phase 3
~Apr 2014
→ ~Jul 2015
NDA/BLA
~Oct 2015
→ ~Jan 2017
Approved
Apr 2017
→ Nov 2028
ApprovedCurrent
NCT07600063
2,796 pts·Migraine
2017-04→2028-11·Terminated
NCT03894692
2,847 pts·Migraine
2019-01→2027-04·Recruiting
NCT07066250
539 pts·Migraine
2018-06→2027-03·Terminated
6,182 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2027-03-1812mo awayPh3 Readout· Migraine
2027-04-201.1y awayPh3 Readout· Migraine
2028-11-222.6y awayPh3 Readout· Migraine
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Termina…
Approved
Termina…
Approved
Recruit…
Catalysts
Ph3 Readout
2027-03-18 · 12mo away
Migraine
Ph3 Readout
2027-04-20 · 1.1y away
Migraine
Ph3 Readout
2028-11-22 · 2.6y away
Migraine
RecruitingTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07600063 | Approved | Migraine | Terminated | 2796 | EFS |
| NCT03894692 | Approved | Migraine | Recruiting | 2847 | ACR20 |
| NCT07066250 | Approved | Migraine | Terminated | 539 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 |